Talabostat mesylate

HCID 11522448

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

CAS: 150080-09-4
Standard-SMILES: CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O.CS(=O)(=O)O
InChIKey: OXYYOEIGQRXGPI-WSZWBAFRSA-N
Summenformel: C10H23BN2O6S
Durchschnittliche Molmasse: 310,18 g/mol
Monoisotopische Masse: 310,13698786

Überblick

Talabostat Mesylate is the mesylate salt of an orally active small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.

Namen und Bezeichner

Bevorzugter Name: Talabostat mesylate
IUPAC: [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid;methanesulfonic acid
Englischer Name: [(2R)-1-[(2S)-2-Amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid mesylate
Summenformel: C10H23BN2O6S
Molmasse: 310.17

Namen und Synonyme

Talabostat mesylate150080-09-4Methanesulfonic acid ((R)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)boronic acid (1:1)Talabostat mesilate[(2R)-1-[(2S)-2-Amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid mesylateMFCD13194906TalabostatmesylateTalabostat mesylate [USAN]Talabostat (mesylate)Talabostat mesylate (USAN)V8ZG4Y1B51PT100

Weitere Namen anzeigen

CS-1219PT100 mesylateVal-boroPro mesylateAdrafinil Impurity 6Talabostat (PT-100) ，S8455Talabostat-mesylate, PT-100methanesulfonic acid - [A83080]

EX-A2166HY-13233A((2R)-1-((2S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)boronic acid methanesulfonate[(2R)-1-[(2S)-2-amino-3-methyl-butanoyl]pyrrolidin-2-yl]boronic acid;methanesulfonic acidC10H23BN2O6S[(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid;methanesulfonic acidMethanesulfonic acid ((R)-1-((S)-2-amino-3-methyl-butanoyl)pyrrolidin-2-yl)boronic acid (1:1)UNII-V8ZG4Y1B51

Datenbank-Bezeichner

CAS: 150080-09-4
PubChem CID: 11522448
DTXSID: DTXSID70164466
ChEMBL: CHEMBL3545064
UNII: V8ZG4Y1B51

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA): 150 Å²
H-Brücken-Donoren: 4
H-Brücken-Akzeptoren: 7
Frei drehbare Bindungen: 3
Schwere Atome: 20
Formalladung: 0
Komplexität: 328

Physikochemische Eigenschaften

Schmelzpunkt: 160 °C · >160°C (dec.)
storage temp.: 2 · under inert gas (nitrogen or Argon) at 2–8 °C
Löslichkeit: Soluble in DMSO (up to at least 25 mg/ml)
Aggregatzustand: solid
Farbe: White
Stabilität: 1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChI: 1S/C9H19BN2O3.CH4O3S/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15;1-5(2,3)4/h6-8,14-15H,3-5,11H2,1-2H3;1H3,(H,2,3,4)/t7-,8-;/m0./s1
InChIKey: OXYYOEIGQRXGPI-WSZWBAFRSA-N
SMILES: B(O)(O)[C@H]1N(CCC1)C(=O)[C@@H]([N+H3])C(C)C.[S](=O)(=O)([O-])C

Sicherheit und Regulatorisches

Sicherheitsdaten

wgk: WGK 3
Speicherklasse: 11 - Combustible Solids

Chemie und Industrie

Anwendungen · 2 Einträge

BeschreibungTalabostat is a non-selective inhibitor of dipeptidyl peptidases (DPPs), including DPP-4, DPP-7, DPP-8, DPP-9, fibroblast activation protein (FAP), and prolyl endopeptidase (PREP; IC50s = >4, 310, 4, 11, 560, and 390 nM, respectively). It inhibits proliferation of superantigen-stimulated human peripheral blood mononuclear cells (PBMCs; IC50 = ~10 nM). Talabostat (5 μg twice per day) increases expression of a variety of cytokines, including those encoding IL-1β, IL-6, and G-CSF, and chemokines in tumors and tumor-draining lymph nodes in a WEHI-164 fibrosarcoma mouse model. It reduces tumor growth in WEHI-164, MM45T.Sp, and MM52.T fibrosarcoma, EL-4 and A20/2J lymphoma, B16/F10 melanoma, and P815 mastocytoma syngeneic mouse models. Talabostat also increases the efficacy of the antitumor antibodies rituximab and trastuzumab in Namalwa B cell lymphoma and LS180 colon carcinoma mouse xenograft models, respectively.

VerwendenTreatment of cancer; hematopoetic stimulant.